The Peter Doherty Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Melbourne Australia (2014)

Organization Overview

First Clinical Trial
2016
NCT02765126
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

The Peter Doherty Institute for Infection and Immunity

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Communicable Diseases (Phase 3)

Gram-Positive Bacterial Infections (Phase 1)

Hemolysis (Phase 1)

HIV Infections (Phase 2)

Infections (Phase 3)

Pharyngitis (Phase 1)

Streptococcal Infections (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 23